Signal from the log
Microbiotica
36 M£ · Series C · United Kingdom · Biotech
Microbiotica, issue du Wellcome Sanger Institute, développe MB310, une gélule quotidienne de huit souches de bactéries intestinales contre la rectocolite hémorragique. Premier closing de série C mené par la British Business Bank, pour une phase 2 contre placebo après une phase 1b positive.
Article
Announced on , logged by the watch of 16 October 2026.
- Operation
- Funding round
- Announced amount
- 36 M£
- Stage
- Series C
- Country
- United Kingdom
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by British Business Bank , with Tencent , IP Group , Cambridge Innovation Capital , Flerie Invest , Seventure Partners
Provenance
Source eu-startups
Logged on 16 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.